Frequency of Sexual Dysfunction In Women With Rheumatic Diseases PDF Print E-mail
Sunday, 07 July 2013 20:08
Sexuality is part of human life and of quality of life, accounting for individual well-being. It relates not only to sexual intercourse itself, but also to a whole spectrum that ranges from self-image and self-valuing to relationship with the ‘Other’. Appropriate sexual activity comprises phases from sexual arousal to relaxation, with pleasure and satisfaction.

Sexual dysfunction is a change in a phase of the sexual activity that can culminate in frustration, pain, and a reduction in the number of sexual intercourses. Some studies have shown a prevalence of sexual dysfunction in the general female population of as much as 40%. Chronic diseases are known to influence the quality of sexual life, but their effect is little studied, and sexual dysfunction, little diagnosed. This is due to two reasons: patients do not report their sexual dysfunctions because of shame or frustration, and physicians rarely ask their patients about those dysfunctions.

When asked, health professionals allege to have little time for consultation, lack of privacy in their medical offices, and lack of ability to discuss the issue. In addition, patients tend to avoid speaking about that subject. Recently, the Association Nationale de Défense Contre l’Arthrite Rhumatoïde (French Association for Rheumatoid Arthritis) has sent, via e-mail, a questionnaire about sexuality to their members. Only 38% responded, and 70% reported a negative impact of the disease on their sexual life. Seventy-two per cent reported never having spoken with their physicians about sexuality.

Studies on the Brazilian population that could help to delineate the real impact of rheumatic diseases on sexual functioning still lack. Knowing the extension of the problem is necessary, so that therapeutic possibilities can be provided, because sexual dysfunction is one of the major determinants of reduced quality of life.

This study aimed at assessing the prevalence of sexual dysfunction in women followed up in the Rheumatology Outpatient Clinic of the Hospital Universitário de Brasília (HUB) and the Hospital das Clínicas of the Universidade de São Paulo (HC-FMUSP), who have the following rheumatic diseases: systemic lupus erythematosus (SLE); rheumatoid arthritis (RA); systemic sclerosis (SSc); antiphospholipid antibody syndrome (APLS); and fibromyalgia (FM).

To continue reading the full study, please download from the link provided below.

 
More articles :

» Rare Disease Research Teams Receive Over $17m In Funding

(CIHR) has formed 9 new research teams that will focus on rare diseases. Funding from the CIHR will total $15.4 million over five years, primarily through the Institute of Genetics and the Institute of Nutrition, Metabolism, and Diabetes, while...

» Development of an Activity Index for Localized Scleroderma (Morphea)

E. Lanciano, A. CHIALà, E. Praino, V. Grattagliano, M. Covelli, F. Iannone, G. Lapadula Reumatologia Universitaria, Policlinico, Bari, ItalyAnn Rheum Dis 2011;70(Suppl3):481Background: Morphea is a skin disorder characterized by fibrosis. It...

» Enhanced Survival Found With Early Detection of Scleroderma-Associated PAH

Early detection of incident systemic sclerosis–associated enhanced survival in a prospective cohort study of 131 patients from the multicenter PHAROS, according to data presented at the annual meeting of the American College of Rheumatology.The...

» Children Get Scleroderma Too

Juvenile is a rare childhood condition characterized by fibrosis of the skin and internal organs. Clinical manifestations of childhood Scleroderma are different from adult disease and early recognition, correct classification and treatment can...

» What is Chelation Therapy?

Chelation (pronounced key-LAY-shun) therapy is a chemical process in which a synthetic solution-EDTA (ethylenediaminetetraacetic acid) is injected into the bloodstream to remove heavy metals and/or minerals from the body. Chelation means "to grab"...

» Sonographic Evaluation of Pediatric Localized Scleroderma Preliminary Disease Assessment Measures

Background: Our earlier work in the ultrasonograpy of localized scleroderma (LS) suggests that altered levels of echogenicity and vascularity can be associated with disease activity. Utrasound is clinically benign and readily available, but can be...

Comments  

 
+1 #1 cindy haan 2013-07-09 14:10
Taking any antidepressants along with scleroderma and having Pulmonary hypertension that often occurs with it...makes the dysfunction much worse. Noticed it as soon as I took Zoloft and cymbalta.
Report to administrator